OTIC News and Press, Otonomy Inc. From 06/12/19

SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the Raymond...

Otonomy, Inc. (OTIC) Q1 2019 Results Earnings Conference Call May 06, 2019, 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners David Weber - President and CEO Kathie Bishop - Chief Scientific Officer Paul Cayer - Chief Financial and Business Officer Conference...

Otonomy (NASDAQ: OTIC ): Q1 GAAP EPS of -$0.39 beats by $0.06 . More news on: Otonomy, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 OTIPRIO ®  co-promotion agreement completed with Glenmark Therapeutics OTIVIDEX™  Phase 3 trial in Ménière’s disease on track for results...

SAN DIEGO, May 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the signing of a co-promotion agreement with Glenmark Therapeutics Inc., USA, a wholly-owned su...

SAN DIEGO, May 01, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that the company will host one-on-one meetings with investors at the 5th Annual SunTrust R...

SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the first quarter 2019 as well as provide a corporate up...

Otonomy (NASDAQ: OTIC ) has initiated a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine, in patients with tinnitus. More news on: Otonomy, Inc., Healthcare stocks news, Read more ...

SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the initiation of a Phase 1/2 clinical trial of OTO-313, a sustained-exposure formulation of ...

The following slide deck was published by Otonomy, Inc. in conjunction with this Read more ...